09:07 AM EDT, 10/17/2024 (MT Newswires) -- Immutep ( IMMP ) said Thursday that it has completed recruitment for the first part of its early-stage trial for IMP761, a LAG-3 immunotherapy aimed at treating autoimmune diseases. The part A, single dose, of the placebo-controlled, double-blind trial reported no safety issues following drug administration, the company said. The trial will now...

02:44 PM EDT, 10/17/2024 (MT Newswires) -- Kezar Life Sciences ( KZR ) said Thursday the Independent Data Monitoring Committee has recommended the Portola phase 2a trial of zetomipzomib in patients with autoimmune hepatitis to proceed without modification following its review. Kezar said the trial, which is being conducted in the US, has so far not shown any grade 4...

02:44 PM EDT, 10/17/2024 (MT Newswires) -- Microsoft ( MSFT )-backed (MSFT) OpenAI and Bain are extending their partnership to sell OpenAI's ChatGPT and other AI tools to the consulting firm's clients, The Wall Street Journal reported Thursday. The companies started a sales partnership in 2023 and in August 13,000 Bain consultants got licenses for ChatGPT Enterprise, according to the...

02:31 PM EDT, 10/17/2024 (MT Newswires) -- Greenheart Gold ( GHRTF ) on Thursday said it closed a brokered private placement financing that raised $36 million as it placed 72.09-million shares priced at $0.50 each. Proceeds will be used to acquire properties mineral properties in Guyana and Suriname, for working capital and general corporate purposes. Greenheart Gold ( GHRTF )...